NASDAQ:FLXN - Flexion Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.39 +0.40 (+3.34 %) (As of 03/21/2019 03:48 PM ET)Previous Close$11.99Today's Range$11.91 - $12.4752-Week Range$10.98 - $29.10Volume25,707 shsAverage Volume650,733 shsMarket Capitalization$470.70 millionP/E Ratio-2.76Dividend YieldN/ABeta1.7 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Receive FLXN News and Ratings via Email Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FLXN Previous Symbol CUSIPN/A CIK1419600 Webwww.flexiontherapeutics.com Phone781-305-7777Debt Debt-to-Equity Ratio1.35 Current Ratio7.78 Quick Ratio7.58Price-To-Earnings Trailing P/E Ratio-2.76 Forward P/E Ratio-3.29 P/E GrowthN/A Sales & Book Value Annual Sales$22.52 million Price / Sales20.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book4.26Profitability EPS (Most Recent Fiscal Year)($4.49) Net Income$-169,660,000.00 Net Margins-753.24% Return on Equity-102.16% Return on Assets-48.93%Miscellaneous EmployeesN/A Outstanding Shares37,990,000Market Cap$470.70 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions What is Flexion Therapeutics' stock symbol? Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN." How were Flexion Therapeutics' earnings last quarter? Flexion Therapeutics Inc (NASDAQ:FLXN) posted its earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.22) by $0.06. The specialty pharmaceutical company had revenue of $3.80 million for the quarter, compared to analyst estimates of $3.96 million. Flexion Therapeutics had a negative return on equity of 102.16% and a negative net margin of 753.24%. View Flexion Therapeutics' Earnings History. When is Flexion Therapeutics' next earnings date? Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Flexion Therapeutics. What price target have analysts set for FLXN? 5 analysts have issued 1 year price targets for Flexion Therapeutics' shares. Their predictions range from $11.49 to $36.00. On average, they anticipate Flexion Therapeutics' stock price to reach $25.4980 in the next year. This suggests a possible upside of 106.8% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics. What is the consensus analysts' recommendation for Flexion Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics. What are Wall Street analysts saying about Flexion Therapeutics stock? Here are some recent quotes from research analysts about Flexion Therapeutics stock: 1. Northland Securities analysts commented, "We believe Zilretta’s superior safety and efficacy vs. IR-corticosteroids will make it the intra-articular injection of choice for treating OAK and other indications. We anticipate approval of the sNDA for repeat administration for OAK in mid-October. This, along w/ Zilretta receipt of J code (J3304) effective Co.’s pursuit of additional indications, i.e., hip and shoulder, we believe will support peak US sales >$750MM. Flexion reported 4Q Zilretta sales of $9.5MM, aligned w/ consensus. R&D and SG&A expense line items for the 4Q period totaled $14.9MM and $30.6MM, respectively, w/ EPS for the 4Q period at ($1.07) vs. the ($1.15) consensus." (3/1/2019) 2. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (2/27/2019) Has Flexion Therapeutics been receiving favorable news coverage? Media coverage about FLXN stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Flexion Therapeutics earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Who are some of Flexion Therapeutics' key competitors? Some companies that are related to Flexion Therapeutics include Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Xencor (XNCR), Allakos (ALLK), Pacira Pharmaceuticals (PCRX), Myovant Sciences (MYOV), Wave Life Sciences (WVE), Puma Biotechnology (PBYI), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Gossamer Bio (GOSS), Innoviva (INVA), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT) and Theravance Biopharma (TBPH). What other stocks do shareholders of Flexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Celgene (CELG), Cara Therapeutics (CARA), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), TherapeuticsMD (TXMD), Omeros (OMER), Micron Technology (MU) and Inovio Pharmaceuticals (INO). Who are Flexion Therapeutics' key executives? Flexion Therapeutics' management team includes the folowing people: Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)Mr. David A. Arkowitz, Chief Financial Officer (Age 58)Scott Young, VP of Corp. Communications & Investor Relations Who are Flexion Therapeutics' major shareholders? Flexion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.55%), Peregrine Capital Management LLC (2.04%), Rhenman & Partners Asset Management AB (1.34%), Northern Trust Corp (1.18%), Geode Capital Management LLC (1.02%) and Geode Capital Management LLC (1.02%). Company insiders that own Flexion Therapeutics stock include David Arkowitz, Frederick W Driscoll, Mark S Levine, Mark Stejbach, Michael D Clayman, Neil Bodick and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics. Which institutional investors are selling Flexion Therapeutics stock? FLXN stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Zweig DiMenna Associates LLC, Squarepoint Ops LLC, Rhenman & Partners Asset Management AB, GAM Holding AG, Northern Trust Corp, Gagnon Advisors LLC and BlackRock Inc.. Company insiders that have sold Flexion Therapeutics company stock in the last year include Mark S Levine, Michael D Clayman and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics. Which institutional investors are buying Flexion Therapeutics stock? FLXN stock was acquired by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Canada Pension Plan Investment Board, Virtu Financial LLC, Alps Advisors Inc., Rhumbline Advisers, Metropolitan Life Insurance Co. NY, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include David Arkowitz, Mark Stejbach, Michael D Clayman, Neil Bodick and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics. How do I buy shares of Flexion Therapeutics? Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Flexion Therapeutics' stock price today? One share of FLXN stock can currently be purchased for approximately $12.33. How big of a company is Flexion Therapeutics? Flexion Therapeutics has a market capitalization of $468.42 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. What is Flexion Therapeutics' official website? The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com. How can I contact Flexion Therapeutics? Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected] MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 459 (Vote Outperform)Underperform Votes: 263 (Vote Underperform)Total Votes: 722MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: What are the risks of holding treasury bonds?